Dylan Steen, MD
Cardiovascular Disease · Cincinnati, OHNPI 1073711826
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $88,141 of the $90,553 with a category attached, or 97.3%. Sanofi-aventis U.S. LLC accounts for 97.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $29,584 and has fallen 98.7% since, to $373 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $2208.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$88K
- Novo Nordisk$1K
- Bayer$381
- Novartis$363
- Amgen$297
- Cleerly, Inc.$156
- plus $214 from 4 others
Across 18 payments — averaging $21,023 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$337K
- Amgen$41K
What the payments were for
- Consulting fees$88,14197%
- Food & beverage$2,2192%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 6 | $88,141 |
| Novo Nordisk | 18 | $1,000 |
| Bayer | 4 | $381 |
| Novartis | 2 | $363 |
| Amgen | 4 | $297 |
| Cleerly, Inc. | 1 | $156 |
| Cardiovascular Systems Inc. | 1 | $94 |
| AstraZeneca | 2 | $73 |
| Johnson & Johnson | 2 | $33 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$79,981
- LOVENOX$8,160
- Ozempic$327
- Cleerly Ischemia$156
- Cleerly Labs$156
- Repatha$104
How this compares
$90,553 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spironolactone | 20 | $68 |
| Potassium Chloride | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cincinnati
- Kamal ShemisaCincinnati$314K
- Richard BaeCincinnati$136K
- Joel FormanCincinnati$64K
- Freidoon GhaziCincinnati$56K
- Wojciech MazurCincinnati$44K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.